Abstract: Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.

Abstract: The invention relates to therapeutic uses of elsiglutide, particularly for protecting and stimulating bone marrow and peripheral blood cell type activity or immune-response in patients compromised due to the administration of chemotherapeutic agents. The invention further provides uses of elsiglutide to enhance the antitumor activity of cytotoxic chemotherapeutic agents and target specific biological agents.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.

Abstract: Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.

Abstract: The invention relates to therapeutic uses of elsiglutide, particularly for protecting and stimulating bone marrow and peripheral blood cell type activity or immune-response in patients compromised due to the administration of chemotherapeutic agents. The invention further provides uses of elsiglutide to enhance the antitumor activity of cytotoxic chemotherapeutic agents and target specific biological agents.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.

Abstract: An embodiment of the present invention is a method of controlling an Organic Rankine Cycle system, the system comprising at least one feed pump (2), at least one heat exchanger (3), an expansion turbine (5) and a condenser (6), the organic Rankine Cycle comprising a feeding phase of an organic working fluid, a heating and vaporization phase of the same working fluid, an expansion and condensation phase of the same working fluid, wherein said method controls an adjusted variable (X), which is a function of an overheating of the organic fluid, by means of a controller (20) that acts by varying a control variable (Y), which is a parameter of the organic fluid in its liquid phase, and wherein the adjusted variable (X) is a temperature difference ([increment]T) between a current temperature of the organic fluid in vapor phase at the turbine inlet and a temperature threshold (Tlim), under which the expansion phase involves the formation of a liquid phase of the organic fluid.

Abstract: Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.

Abstract: Combinations of netupitant and palonosetron, and methods of using such combinations to treat various pain states and irritable bowel syndrome, are provided.

Abstract: The invention relates to an ORC (Organic Rankine Cycle) for the conversion of thermal energy into electric energy, comprising at least one heat exchanger unit for re-superheating the working fluid by means of the thermovector fluid from the hot source, between the discharge of the first expander and the input of the second expander, and a regenerator unit including a first regenerator and at least one second regenerator for regenerating the working fluid in at least two successive stages, in said first regenerator and at least in said second regenerator respectively, with an additional regenerative heat exchange along the flow line connecting the liquid working fluid output of the second regenerator to the liquid working fluid input of the first regenerator.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor.

Abstract: Combinations of netupitant and palonosetron, and methods of using such combinations to treat various pain states and irritable bowel syndrome, are provided.